Navigation Links
Psychemedics Corporation Announces 2008 Year End Results
Date:2/18/2009

182 58,613 ------ ------ Total Assets 12,627,785 15,560,768 ========== ========== LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable 644,894 488,640 Accrued expenses 1,268,924 951,242 Deferred revenue 154,080 242,955 ------- ------- Total Liabilities 2,067,898 1,682,837 SHAREHOLDERS' EQUITY: Preferred stock, $.005 par value; authorized 872,521 shares; none outstanding Common stock; $.005 par value; authorized 50,000,000 shares; 5,843,068 shares issued in 2008 and 5,811,982 shares issued in 2007 29,215 29,060 Paid-in capital 27,118,743 26,539,764 Accumulated deficit (6,614,114) (3,527,269) Less - Treasury stock, at cost; 647,304 shares in 2008 and 586,197 shares in 2007 (9,973,957) (9,163,624) ---------- ---------- Total shareholders' equity 10,559,887 13,877,931 Total Liabilities & Shareholder Equity 12,627,785 15,560,768 ========== ==========

    Contact:
    Raymond Ruddy
    Vice President and Controller
    (978) 206-8220
    raymondr@psychemedics.com


'/>"/>
SOURCE Psychemedics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Psychemedics Corporation Authorizes A 250,000 Share Stock Repurchase Program
2. Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan)
3. NanoBio Corporation Raises $12 Million in Series B Financing
4. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers
5. Newbridge Securities Corporation Forms BioVentures Division
6. Volcano Corporation Presentation at Roth Capital Partners Conference to Be Webcast
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
8. Mirixa Corporation and the APhA Foundation Finalize Partnership
9. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
10. ETHEX Corporation Issues Nationwide Voluntary Recall of Products
11. Ther-Rx Corporation Issues Nationwide Voluntary Recall of Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Costa Mesa, CA (PRWEB) , ... July 01, 2015 , ... ... and traumatic brain injury (TBI) using single photon emission computed tomography (SPECT) ... Columbia. The study, which examined over 20,000 brain scans and is believed to ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that ... in Philadelphia, PA. , The presentation took place on Tuesday, June 16 ... for the development of APX3330 for the treatment of pancreatic cancer. A copy ...
(Date:6/30/2015)... June 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") ... shares of Resverlogix have approved the resolutions relating ... Limited of 5,600,000 units at a price of ... unit being comprised of one common share and ... of approximately CAD$15 million; and (ii) the amendment ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... SAN MATEO, Calif., July 22, 2011 NeurogesX, Inc. ... on developing novel pain management therapies, today announced that ... purchase agreement in connection with a private placement to ... standard closing conditions, is expected to receive approximately $20 ...
... RO, ROG; OTCQX: RHHBY) announced today that the cobas ... for use in colorectal cancer. The cobas ... of colorectal cancer tissue that are predictive of individual ... antibody therapies. "By quickly and reliably ...
... have created a molecular polyhedron, a ground-breaking assembly that ... and consumer products, including magnetic and optical materials. ... the journal Science , was conducted by researchers ... Molecular Design Institute and the University of Milan,s Department ...
Cached Biology Technology:NeurogesX, Inc. Announces $20 Million Private Placement 2NeurogesX, Inc. Announces $20 Million Private Placement 3NeurogesX, Inc. Announces $20 Million Private Placement 4KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark 2KRAS Diagnostic Test That Assists With Personalized Treatment of Colorectal Cancer Receives CE Mark 3Chemists create molecular polyhedron -- and potential to enhance industrial and consumer products 2
(Date:6/24/2015)... 24, 2015 The biologics safety testing market ... for the market include growth of the pharmaceutical and ... launches. Over the years, the number of drug approvals ... 2010, the FDA approved 225 drug applications and Health ... Europe accounted for 3,822 of the ...
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... DURHAM, N.C. -- By mimicking the way embryonic stem cells ... believe they have taken an important first step toward growing ... disease. In a series of experiments using mouse embryonic ... own design to fashion a three-dimensional "patch" made up of ...
... release is available in Spanish . , ... fruits, nuts, whole grains and fish- appear less likely to ... Navarra, published in the October issue of Archives of ... has been found to be lower in Mediterranean than Northern ...
... BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader ... a member of the Oracle® PartnerNetwork, is showcasing its ... being held at the Moscone Center in San Francisco ... the Oracle Identity Assurance Partner Alliance, BIO-key will provide ...
Cached Biology News:New strategy for mending broken hearts? 2Mediterranean diet associated with reduced risk of depression 2BIO-key(R) International to Exhibit at Oracle(R) OpenWorld 2BIO-key(R) International to Exhibit at Oracle(R) OpenWorld 3
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Myeloid Marker (BM-1)...
Request Info...
Biology Products: